Diligence memo · auto-generated · as of July 2, 2026
Triad Life Sciences Inc.
Triad Life Sciences Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Triad Life Sciences Inc. operates in Biotechnology, based in MEMPHIS.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Triad Life Sciences Inc. has raised $17M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $6.6M on 2020-04-06.
Most recent recorded round closed around 2020-04-06.
Valuation (modeled)modeled
Provath models Triad Life Sciences Inc. at approximately $238M (range $7.2M–$1.3B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.32× the median modeled value of Series A Biotechnology companies in 2019–2021 (216 peers) — value vs value, same stage and era. Within the normal band (132% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 5 months.
Last raise 6.2 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.3× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 65% of Biotechnology peers (4293 compared).
Modeled value ranks above 74% of those peers.
Closest niche peers: TRACT Therapeutics, Inc., TechAccel, LLC, Arrakis Therapeutics, Inc., Trident Labs, Inc., Meissa Vaccines Inc.
Peoplefiled
10 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.